ReviewNature reviews. Cardiology2011
Restenosis after PCI. Part 2: prevention and therapy.
Review in Nature reviews. Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study.PloS one · 2012Pooled it
- Trial
- Prevascularized grafts with spatially organized MSC spheroids to accelerate therapeutic angiogenesis in ischemic disease.Angiogenesis · 2026Article
- Hemodynamic Significance of APEXCT Coronary Angiography Combined With Dynamic CT Myocardial Perfusion Imaging in Assessing Restenosis After Coronary Stenting.The Kaohsiung journal of medical sciences · 2026Article
- Macrophage pyroptosis inhibition alleviates postinjury neointimal formation and vascular restenosis.Journal of translational medicine · 2026Article
- Association of metabolic indices with in-stent restenosis and its angiographic severity after drug-eluting stent implantation: a case-control study.Frontiers in endocrinology · 2026Article
- The RNA-binding protein RBPMS inhibits smooth muscle cell-driven vascular remodeling in atherosclerosis and vascular injury.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- ROS-responsive & scavenging NO nanomedicine for vascular diseases treatment by inhibiting endoplasmic reticulum stress and improving NO bioavailability.Bioactive materials · 2024Article
- Review
- Synthesis of Prussian Blue Nanoparticles and Their Antibacterial, Antiinflammation and Antitumor Applications.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Uncertainty quantification of a three-dimensional in-stent restenosis model with surrogate modelling.Journal of the Royal Society, Interface · 2022Article
- Vascular Stem/Progenitor Cells in Vessel Injury and Repair.Frontiers in cardiovascular medicine · 2022Review
- Upregulating CXCR7 accelerates endothelial progenitor cell-mediated endothelial repair by activating Akt/Keap-1/Nrf2 signaling in diabetes mellitus.Stem cell research & therapy · 2021Article
- Histopathologic response after hydrophilic polyethylene glycol-coating stent and hydrophobic octadecylthiol-coating stent implantations in porcine coronary restenosis model.Journal of materials science. Materials in medicine · 2020Article
- AMD3100 and SDF‑1 regulate cellular functions of endothelial progenitor cells and accelerate endothelial regeneration in a rat carotid artery injury model.Molecular medicine reports · 2020Article
- Long Noncoding RNAs in Atherosclerosis and Vascular Injury: Pathobiology, Biomarkers, and Targets for Therapy.Arteriosclerosis, thrombosis, and vascular biology · 2020Review
- A particle-based model for endothelial cell migration under flow conditions.Biomechanics and modeling in mechanobiology · 2020Article
- Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting.Acta Cardiologica Sinica · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The techniques and materials used during percutaneous coronary intervention have advanced considerably over the past 3 decades, yet restenosis remains one of the major drawbacks of this procedure. Many innovative technologies, including drug-eluting stents, with or without specific polymers, and fully biodegradable stents have been and continue to be developed in the search for a safe and effective antirestenosis therapy. Remarkable advances in stent design and nanoparticle delivery systems ('nanovehicles') have already fueled revolutionary changes in the prevention and treatment of in-stent restenosis. In this Review we provide an overview of the latest innovations for optimizing outcomes of coronary stenting, and up-to-date information about prevention and treatment of in-stent restenosis.
Indexed as
Identifiers
21989052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.